AU2003290009A1 - Diagnostics and therapeutics for diseases assosciated with 5-hydroxytryptamine (serotonin) receptor 2b (5-hteb) - Google Patents

Diagnostics and therapeutics for diseases assosciated with 5-hydroxytryptamine (serotonin) receptor 2b (5-hteb)

Info

Publication number
AU2003290009A1
AU2003290009A1 AU2003290009A AU2003290009A AU2003290009A1 AU 2003290009 A1 AU2003290009 A1 AU 2003290009A1 AU 2003290009 A AU2003290009 A AU 2003290009A AU 2003290009 A AU2003290009 A AU 2003290009A AU 2003290009 A1 AU2003290009 A1 AU 2003290009A1
Authority
AU
Australia
Prior art keywords
assosciated
hteb
hydroxytryptamine
serotonin
therapeutics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003290009A
Inventor
Ulf Bruggemeier
Stefan Golz
Holger Summer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of AU2003290009A1 publication Critical patent/AU2003290009A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003290009A 2002-12-23 2003-12-11 Diagnostics and therapeutics for diseases assosciated with 5-hydroxytryptamine (serotonin) receptor 2b (5-hteb) Abandoned AU2003290009A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02028754 2002-12-23
EP02028754.6 2002-12-23
PCT/EP2003/014031 WO2004057338A1 (en) 2002-12-23 2003-12-11 Diagnostics and therapeutics for diseases assosciated with 5-hydroxytryptamine (serotonin) receptor 2b (5-hteb)

Publications (1)

Publication Number Publication Date
AU2003290009A1 true AU2003290009A1 (en) 2004-07-14

Family

ID=32668739

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003290009A Abandoned AU2003290009A1 (en) 2002-12-23 2003-12-11 Diagnostics and therapeutics for diseases assosciated with 5-hydroxytryptamine (serotonin) receptor 2b (5-hteb)

Country Status (3)

Country Link
EP (1) EP1616192A1 (en)
AU (1) AU2003290009A1 (en)
WO (1) WO2004057338A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2142721A1 (en) * 1992-08-20 1994-03-03 Ian T. Forbes Condensed indole derivatives as 5ht and 5ht antagonists
ES2208382T3 (en) * 1999-07-30 2004-06-16 Pharmagene Laboratories Ltd USE OF 2-AMINO-4- (4-FLUORONAFT-1-IL) -6-ISOPROPILPIRAMIDINA IN THE TREATMENT OF GASTROINTESTINAL ALTERATIONS.
EP1270568A1 (en) * 2001-06-19 2003-01-02 Biofrontera Pharmaceuticals AG 1-methyl-4-(3-ethoxy-9h-thioxanthene-ylidene)-piperidine and its use as 5-HT2B and/or H1 antagonist
EP1306376A1 (en) * 2001-10-25 2003-05-02 Biofrontera Pharmaceuticals AG Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist
FR2837708B1 (en) * 2002-04-02 2005-02-04 Schwarz Pharma Lab USE OF 8'-HYDROXYDIHYDROERGOTAMINE FOR THE MANUFACTURE OF A MEDICINE AGAINST MIGRAINE
FR2837707B1 (en) * 2002-04-02 2005-02-04 Schwarz Pharma Lab USE OF 8'-HYDROXYDIHYDROERGOTAMINE FOR AN ANXIOLYTIC DRUG

Also Published As

Publication number Publication date
WO2004057338A1 (en) 2004-07-08
EP1616192A1 (en) 2006-01-18

Similar Documents

Publication Publication Date Title
AU2003250877A1 (en) Nr3b1 nuclear receptor binding 3-substituted pyrazoles
AU2002360819A1 (en) Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
AU2003238339A1 (en) Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
AU2003290009A1 (en) Diagnostics and therapeutics for diseases assosciated with 5-hydroxytryptamine (serotonin) receptor 2b (5-hteb)
AU2003240589A1 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 4 (gpr4)
AU2003205627A1 (en) Diagnostics and therapeutics for diseases associated with gpr72
AU2003293832A1 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 2c (5-ht2c)
AU2003218638A1 (en) Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
AU2003273994A1 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
AU2003229767A1 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
AU2003250128A1 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 37 (gpr37)
AU2003206749A1 (en) Diagnostics and therapeutics for diseases associated with the gpr65 receptor
AU2003281525A1 (en) Serotonin receptor
AU2003240720A1 (en) Diagnostics and therapeutics for diseases associated with somatostatin receptor 5 (sstr5)
AU2003279308A1 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 73a (gpr73a)
AU2003229753A1 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
AU2003240469A1 (en) Diagnostics and therapeutics for diseases associated with neuromedin b receptor (nmb)
AU2003250221A1 (en) Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 6(cxcr6)
AU2003250165A1 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19)
AU2003274083A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 10a (pde10a)
AU2003274005A1 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 6 (gpr6)
AU2003221502A1 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 10 (gpr10)
AU2003288250A1 (en) Diagnostics and therapeutics for diseases associated with muscarinic acetylcholine receptor m1 (acm1)
AU2003301892A1 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase